Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

Sequential therapy in renal cell carcinoma

(2010) Bernard Escudier et al.   CANCER

Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy

(2009) Manuela Schmidinger et al.   CANCER TREATMENT REVIEWS

7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN

(2009) S. Bracarda et al.   EJC SUPPLEMENTS

252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)

(2009) C. Porta et al.   EUROPEAN UROLOGY SUPPLEMENTS

Solitary Extramedullary Plasmacytoma of the Vocal Cord in an Adolescent

(2009) Issai Vanan et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on Cardiac Toxicity With Trastuzumab and Radiotherapy: The Question Is Still Ongoing

(2009) Nicolas Magné et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

(2009) M.P. Sablin et al.   JOURNAL OF UROLOGY

First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma

(2008) B. Melichar et al.   ANNALS OF ONCOLOGY

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

(2008) Arkadiusz Z. Dudek et al.   CANCER

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY